Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
M9140 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| M9140 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| M9140 | DRUG | M9140 will be administered every 3 weeks until progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study. There will be 2 dose levels, if the low dose level is tolerated, then M9140 will be escalated to the high dose level. |
Inclusion Criteria: * Participants with documented histopathological diagnosis of locally advanced or metastatic CRC, who were intolerant/refractory to or progressed after standard systemic therapies for the advanced/metastatic stage that included and are restricted to a fluoropyrimidine, irinoteca...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
M9140 is an investigational small molecule being studied for the treatment of solid tumors, including colorectal cancer. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
M9140 is an antibody-drug conjugate (ADC) that targets CEACAM5, a protein expressed on the surface of certain tumor cells. By binding to CEACAM5, the drug aims to deliver a cytotoxic payload directly to cancer cells.
M9140 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The company is conducting clinical trials to evaluate the drug's safety and efficacy.
M9140 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory bodies and is still undergoing clinical trials to assess its safety and potential effectiveness.
M9140 is being studied in a Phase 1 clinical trial with the identifier NCT06806046. This trial is evaluating the drug in Chinese participants with solid tumors, including colorectal cancer, and is currently active but not recruiting participants.
Yes, M9140 is also known as Precemtabart Tocentecan. The drug is referred to by both names in clinical trial documentation, and they refer to the same investigational antibody-drug conjugate.